Drug Trial Radar · NCT03810313
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Last checked: Nov 20, 2026Latest source record: Jan 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
493
Actual
Start
Jul 3, 2019
Primary completion
Jul 26, 2021
Study completion Jul 26, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
Conditions
- Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mgDrug
Solution for injection (intravitreal use)
Aflibercept 2 mgDrug
Solution for injection (Intravitreal use)
Sham injectionOther
Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 24Time frame: Baseline, Week 24
Locations
120 sites in 20 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
La Jolla, California
Novartis Investigative Site
Mountain View, California
Novartis Investigative Site
Santa Barbara, California
Novartis Investigative Site
Colorado Springs, Colorado
Novartis Investigative Site
Fort Myers, Florida
Novartis Investigative Site
St. Petersburg, Florida
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
New Albany, Indiana
Novartis Investigative Site
Leawood, Kansas
Novartis Investigative Site
Lenexa, Kansas
Novartis Investigative Site
Stoneham, Massachusetts
Novartis Investigative Site
Minneapolis, Minnesota
Novartis Investigative Site
Reno, Nevada
Novartis Investigative Site
Bloomfield, New Jersey
Novartis Investigative Site
Charlotte, North Carolina
Novartis Investigative Site
Cleveland, Ohio
Novartis Investigative Site
Cleveland, Ohio
Novartis Investigative Site
Monroeville, Pennsylvania
Novartis Investigative Site
Memphis, Tennessee
Novartis Investigative Site
Nashville, Tennessee
Novartis Investigative Site
Abilene, Texas
Novartis Investigative Site
Arlington, Texas
Novartis Investigative Site
Austin, Texas
Novartis Investigative Site
Austin, Texas
Novartis Investigative Site
Bellaire, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Madison, Wisconsin
Novartis Investigative Site
Albury, New South Wales, Australia
Novartis Investigative Site
Parramatta, New South Wales, Australia
Novartis Investigative Site
Strathfield, New South Wales, Australia
Novartis Investigative Site
Sydney, New South Wales, Australia
Novartis Investigative Site
Hobart, Tasmania, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Québec, Canada
Novartis Investigative Site
Calgary, Alberta, Canada
Novartis Investigative Site
London, Ontario, Canada
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.